Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term once-weekly GLP-1RA and cardiovascular outcomes in type 2 diabetes
ChiCTR2300073001Phase 4Not yet recruiting
- Sponsor
- The Second Affiliated Hospital of Shantou University Medical College
- Start
- Jul 2023
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4, open-label trial of polyethylene glycol loxenatide in type 2 diabetes mellitus (T2DM) and cardiac morbidity (2 arms), sponsored by The Second Affiliated Hospital of Shantou University Medical College. Primary endpoint: 3-point major adverse cardiovascular events (MACE). Planned start Jul 2023; status: not yet recruiting.
02
Drugs
polyethylene glycol loxenatide
03
Conditions
type 2 diabetes mellitus (T2DM)cardiac morbidity
Beyond the preview
Go deeper on ChiCTR2300073001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300073001.